Research Associate Professor
Laboratory: Lab of ADC chemistry
Expertise: Genetics, Non-small cell lung cancer, targeted therapy, drug resistance, PROTAC drugs
Research Interests: Study drug-resistant mechanisms in non-small cell lung cancer; develop new strategies to overcome drug resistance using novel techniques including Proteolysis targeting chimera technology (PROTAC), antibody drug conjugates (ADC) and immunotherapy
Email: songxl@@shanghaitech.edu.cn
Address: Room A402, Y building No.199 Huanke Road, ShanghaiTech University (上海浦东张江环科路199号, 人字楼A402上海科技大学 201210)
Tel: +86-21-20685130
Biography:
2022.8-present
Research associate professor, Cancer Biology
Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University
2019.1-2022.7
Research assistant professor, Cancer Biology
Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University.
2015.3-2018.12
Research assistant professor, Stem Cell Research
Shanghai Institute for Advanced Immunochemical Studies (SIAIS), ShanghaiTech University.
2011.4-2015.2
Postdoc, Cancer Biology
Yale Comprehensive Cancer Center, School of Medicine, Yale University, New Haven CT USA
2004-2010
Ph.D. Genetics
Department of Molecular Biochemistry, Biophysics and Molecular Biology, Iowa State University, IA USA 50010
Selected Grants:
1. National Natural Science Foundation of China
Principle Investigator. (2021-2024) ￥550,000
2. Shanghai Science and Technology Innovation Fund
Principle Investigator. (2020-2023) ￥500,000
3. National Natural Science Foundation of China for Young scholar
Principle Investigator. (2017-2019) ￥190,000
4. Uniting Against Lung Cancer 2012 Legacy Program
Principle Investigator (2013-2015) $100,000
5. Leslie H. Warner Postdoctoral Fellowships for Cancer Research
Principle Investigator (2013) $42,000
Selected Awards:
2021 Best Employee from ShanghaiTech University
2017 Best Employee from ShanghaiTech University
2012 Leslie H. Warner Postdoctoral Fellowships for Cancer Research from Yale Cancer Center
2012 AACR-Axel Ullrich Scholar-in-Training Awards from American Association for Cancer Research
2004 Biotechnology Graduate Fellowship Award from Iowa state university
2004 Best Employee from Shanghai Biochip Co., Ltd.
Professional Affiliations:
2017 - Present, Associate Member, The International Society for Stem Cell Research (ISSCR)
2011 - Present, Associate Member, American Association for Cancer Research (AACR)
2010, Associate Member, American Society for Biochemistry and Molecular Biology
2005, Associate Member, RNA society
Publications:
1. Jiawen Yang; Qiaoliang Zhu; Yifan Wu; Xiaojuan Qu; Haixia Liu; Biao Jiang *; Di Ge*; Xiaoling Song*. Utilization of macrocyclic peptides to target protein-protein interactions in cancer [J]. FRONT. ONCOL. 17 November 2022. Volume 12. Sec. Cancer Molecular Targets and Therapeutics. https://doi.org/10.3389/fonc.2022.992171 (通讯作者, 影响因子: IF:5.738)
2. Xiaojuan Qu #; Haixia Liu #; Xiaoling Song #*; Ning Sun; Hui Zhong; Xing Qiu; Xiaobao Yang*; Jiang, Biao*. Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems[J]. European Journal of Medicinal Chemistry. 2021.DOI: 10.1016/j.ejmech.2021.113328(一作兼共同通讯作者, 影响因子: 7.088)
3. Xiaoling Song#*; Xiaojuan Qu#; Siqi Qu; Biao Jiang*. Novel strategies to target EGFR proteins for degradation and their applications in non-small cell lung cancer [J]. Chinese Journal of Nature,2021,43(6):400-407. DOI: 10.3969/j.issn.0253-9608.2021.06.002
4. Chaowei Ren#; Ning Sun#; Haixia Liu; Ying Kong; Renhong Sun; Xing Qiu; Jinju Chen; Yan Li; Jianshui Zhang; Yuedong Zhou; Hui Zhong; Qianqian Yin; Xiaoling Song*; Xiaobao Yang*; Biao Jiang*. Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. Journal of Medicinal Chemistry, 2021. 64(13),9152-9165. (共同通讯作者, 影响因子: 8.039)
5. Chaowei Ren#; Ning Sun; Ying Kong; Xiaojuan Qu; Haixia Liu; Hui Zhong; Xiaoling Song*; Xiaobao Yang*; Biao Jiang#. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib [J]. European Journal of Medicinal Chemistry, 2021,217: 113335. (共同通讯作者, 影响因子: 7.088)
6. Xiaoling Song#*, Hui Zhong#, Xiaojuan Qu#, Linsong Yang* & Biao Jiang*.(2021).Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras. Medcomm, 2021，2(3),341-350. (一作兼通讯作者)
7. Ning Sun#; Chaowei Ren#; Ying Kong; Hui Zhong; ……; Haifan Lin*; Xiaoling Song*; Xiaobao Yang*; Biao Jiang*; Development of a Brigatinib Degrader (SIAIS117) as a Potential Treatment for ALK Positive Cancer Resistance European Journal of Medicinal Chemistry, 2020 May 1;193:112190. (共同通讯作者, 影响因子: 7.088)
9. Anna Truini, Jacqueline H Starrett, Tyler F Stewart, Kumar Dilip Ashtekar, Zenta Walther, Anna Wurtz, David Lu, Jin H Park, Michelle DeVeaux, Xiaoling Song, Scott Gettinger, Daniel Zelterman, Mark A. Lemmon, Sarah B. Goldberg and Katerina Politi. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clin Cancer Res. 2019 Jun 10. pii: clincanres.0780.2019. doi: 10.1158/1078-0432.CCR-19-0780. [Epub ahead of print] PMID: 31182434
2. David G. McFadden, Katerina Politi, Arjun Bhutkar, Frances K. Chen, Xiaoling Song, Mono Pirun, Philip M. Santiago, Caroline Kim-Kiselak, James T. Platt, Emily Lee, Emily Hodges, Adam P. Rosebrock, Roderick T. Bronson, Nicholas D. Socci, Gregory J. Hannon, Tyler Jacks, and Harold Varmus. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci USA. 2016 Oct 18;113(42):E6409-E6417. Epub 2016 Oct 4. PMID: 27702896
3. Xiaoling Song, Pang-Dian Fan, Amlak Bantikassegn, Udayan Guha, David Threadgill, Harold Varmus and Katerina Politi. ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas. Cancer Research. 2015 Epub Jan 16. DOI: 10.1158/0008-5472.
4. Amlak Bantikassegn, Xiaoling Song, Katerina Politi. Isolation of Epithelial, Endothelial, and Immune Cells From Lungs of Transgenic Mice with Oncogene-Induced Lung Adenocarcinomas. American Journal of Respiratory Cell and Molecular Biology 2014 Oct 27.
5. Valentina Pirazzoli*, Caroline Nebhan*, Xiaoling Song, Zenta Walther, Guoping Cai, Anna Wurtz, Zhongming Zhao, Elisa de Stanchina, Leora Horn, David Carbone, Vincent Miller, Scott Gettinger, William Pao and Katerina Politi. Acquired resistance of EGFR mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of the mTORC1. Cell Reports. 2014 May 22; 7(4): 999-1008.
6. Xiaoling Song, Pang-Dian Fan, Udayan Guha, David Threadgill, Harold Varmus, Katerina Politi. Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR-driven Lung Cancer. Clin Cancer Res. February 1, 2012 18:B35; doi:10.1158/1078-0432.12
7. Ken Takezawa, Valentina Pirazzoli*, Maria E. Arcila*, Caroline A. Nebhan#, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y. Janjigian, Paula J. Spitzler, Mary Ann Melnick, Greg J. Riely, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Katerina Politi, William Pao. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discovery. 2012 Oct; 2(10): 922-933. * or # : authors contributed equally. PMID: 2295664
8. Xiaoling Song, Frederic W. Thalacker and Marit Nilsen-Hamilton. Synergistic and multidimensional regulation of plasminogen activator inhibitor type 1 expression by transforming growth factor type β and epidermal growth factor. The Journal of Biological Chemistry. 2012 Apr 6; 287(15):12520-8. Epub 2012 Feb 10. PMID: 22334677
9. Xiaoling SongMarit NilsenHamilton. EGF cooperates with TGFβ to regulate PAI-1 expression by a synergistic increase in transcription and stabilization of mRNA. FASEB J. 2010 24:lb71.
Patents:
Filed one international PCT patent application for lung cancer therapeutic drugs
Filed two China patent applications for lung cancer therapeutics drugs
申请专利
1. Xiaobao Yang,Biao Jiang,Xiaoling Song,et al. EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF. US17632612[P]. 2022-10-06.
2. YANG Xiaobao,JIANG Biao,SONG Xiaoling,et al. ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF. EP20822481[P]. 2022-07-20.
授权专利
1. 杨小宝, 姜标, 宋肖玲,等. EGFR蛋白降解剂及其抗肿瘤应用. CN202010779188.X[P]. 2020-08-05.
2. 杨小宝, 姜标, 孙仁红,等. 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用. CN201910279248.9[P]. 2019-04-09.
3. 杨小宝,姜标,宋肖玲,等. ALK蛋白降解剂及其抗肿瘤应用. CN201811519739.8[P]. 2018-12-12.
4. YANG Xiaobao,JIANG Biao,SONG Xiaoling,et al. ALK protein degradation agent and anti-tumor application thereof. AU2018382122[P]. 2018-12-12.
5. YANG Xiaobao, JIANG Biao, SUN Renhong,et al. Protein degradation targeting compound, anti-tumor application, intermediate thereof and use of intermediate. AU2019251151[P]. 2019-04-09.
